Back to top
more

Blueprint Medicines (BPMC)

(Delayed Data from NSDQ)

$105.46 USD

105.46
581,688

-2.59 (-2.40%)

Updated May 14, 2024 04:00 PM ET

After-Market: $105.39 -0.07 (-0.07%) 4:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Gilead (GILD) Gears Up to Report Q4 Earnings: Whats in Store?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2023 results.

What Makes Blueprint Medicines (BPMC) a New Buy Stock

by Zacks Equity Research

Blueprint Medicines (BPMC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Reasons to Add Blueprint (BPMC) Stock to Your Portfolio Now

by Zacks Equity Research

Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.

Blueprint (BPMC) Gets EC Nod for Ayvakit Expanded Use, Stock Up

by Zacks Equity Research

Blueprint (BPMC) announces EC approval expanding Ayvakit's indication to include the treatment of adult patients with indolent systemic mastocytosis. The stock gained 5%.

Why Is Gilead (GILD) Up 1.9% Since Last Earnings Report?

by Zacks Equity Research

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Glaxo (GSK) Up 5.3% Since Last Earnings Report?

by Zacks Equity Research

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Repligen (RGEN) Up 21.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 1.7% Since Last Earnings Report?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

How Much Upside is Left in Blueprint Medicines (BPMC)? Wall Street Analysts Think 42.16%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 42.2% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?

by Zacks Equity Research

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

Blueprint (BPMC) Stock Gains 26% on Q3 Earnings & Sales Beat

by Zacks Equity Research

Blueprint (BPMC) climbs 26% on better-than-expected third-quarter 2023 results, driven by increased Ayvakit sales following the drug's label expansion in the United States.

Compared to Estimates, Blueprint Medicines (BPMC) Q3 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Blueprint Medicines (BPMC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 7.95% and 14.09%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Ahan Chakraborty headshot

Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC

by Ahan Chakraborty

Let's look at three biotech/drug companies, BMY, MRK and BPMC, slated to release quarterly results on Oct 26.

AC Immune (ACIU) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

AC Immune (ACIU) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Blueprint Medicines (BPMC) Q3 Earnings Expected to Decline

by Zacks Equity Research

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?

by Zacks Equity Research

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.

Blueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for Blueprint Medicines (BPMC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 15.12% and 27.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up

by Zacks Equity Research

Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.